on this page

The increasing demand for advanced technologies in the pharmaceutical industry is driven by the need to enhance cost-efficiency while maintaining high safety standards of new healthcare developments. A recent industry report shows that the global digital twin technology in pharmaceutical manufacturing market is estimated at US$307.4 million in 2024 and is projected to grow at a CAGR of 31.3% during the forecast period 2024-2034.

A digital twin is a sophisticated virtual model that mirrors a physical object, system, or process in real-time. By leveraging data from sensors, IoT devices, and other sources, a digital twin simulates the behavior, operations, and conditions of its real-world counterpart. This technology has gained significant traction globally and is expected to see continued growth and innovation in 2024 and beyond. The adoption of digital twins is rapidly expanding across various industries, driven by advancements in artificial intelligence (AI), the Internet of Things (IoT), and data analytics.

Pharma 4.0: The Digital Transformation of the Pharmaceutical Industry

Pharma 4.0 represents the digital evolution of the pharmaceutical industry, incorporating advanced technologies and concepts from Industry 4.0. This transformative approach aims to revolutionize pharmaceutical manufacturing and processes by integrating automation, data analytics, IoT, AI, and other cutting-edge technologies. The primary objectives of Pharma 4.0 are to enhance the efficiency, quality, and flexibility of pharmaceutical production, ensure regulatory compliance, and respond more swiftly to market demands.

Pharma 4.0 emphasizes the digitalization of production and distribution processes. However, integrating digital technologies from the outset of new construction projects can provide more realistic and forward-looking solutions. This proactive approach ensures that when projects transition to production and distribution phases, a robust digital foundation is already in place, offering essential data and enabling continued digital integration.

Available Digitalization Solutions

  1. Process Optimization
  2. Real-Time Process Monitoring
  3. Digital Maintenance
  4. Predictive Maintenance
  5. Increased Operational Efficiency
  6. Enhanced Procedural Accuracy

Integrated Solutions

Engineering services consultancy firms, such as AtkinsRéalis, can integrate digitalization into new projects by initially employing 3D modeling techniques in process design.

Key features of this approach include:

  • Powerful Review Functions: Enhanced review capabilities improve the accuracy and efficiency of design evaluations.
  • Seamless Access to Material Data: Facilitates easy access to relevant material data, streamlining the design and procurement processes.
  • Export to ISO Drawings, Plans, and BoMs: Allows for the export of design data into standardized ISO drawings, project plans, and Bills of Materials (BoMs).
  • Integration of Drawings, Data, and Information: Ensures consistent management by integrating all design-related drawings and data.
  • Change Management – Track & Trace: Provides comprehensive tracking and management of any changes throughout the project lifecycle.
  • High Efficiency and Security: Enhances efficiency with built-in data libraries and robust security features.

Advantages of Digitalization in Pharmaceutical Projects

In Bio & Pharmaceutical projects currently being carried out in Asia, Smart Plant, E3D, and BIM are increasingly being utilized. These powerful tools allow for the visualization of each discipline and are integrated to enhance the practical feasibility of route planning, as well as to extract ISO drawings and calculate quantities. Compared to traditional 2D and simple 3D modeling, these methods provide more accurate predictions and can be used in various ways for system management in future operational states.

Advantages of digitalization include:

  • Compliance with Codes and Regulations: Ensures adherence to legal codes and regulatory standards.
  • Integrated Project Delivery (IPD): Supports various project delivery methods, including Integrated Project Delivery.
  • Scalability and Flexibility: Maintains adaptability throughout the project's lifecycle.
  • Enhanced Multi-Disciplinary Collaboration: Improves collaboration and efficiency across different disciplines.
  • Schedule and Cost Savings: Achieves significant time and cost savings during the construction phase.

Furthermore, integrating Building Information Modeling (BIM) allows for comprehensive modeling of the entire structure. When combined with additional data such as schedules and specifications, this model offers powerful solutions applicable for maintenance and project management throughout the production stage.

Embracing Advanced Digitalization

Adopting a more advanced approach through digitalization, as opposed to traditional methods, requires strategic planning, collaboration, and execution. Leveraging case studies and expert insights can ensure successful and efficient project outcomes. Partnering with experts who can collaboratively develop a comprehensive business plan, understand varied requirements, and provide flexible scalability is crucial.

This article was first published at Pharma Nexus.

DISCLAIMER

Please note that you are now leaving the AtkinsRéalis website (legal name: AtkinsRéalis Group inc.) and entering a website maintained by a third party (the "External Website") and that you do so at your own risk.

AtkinsRéalis has no control over the External Website, any data or other content contained therein or any additional linked websites. The link to the External Website is provided for convenience purposes only. By clicking "Accept" you acknowledge and agree that AtkinsRéalis is not responsible, and does not accept or assume any responsibility or liability whatsoever for the data protection policy, the content, the data or the technical operation of the External Website and/or any linked websites and that AtkinsRéalis is not liable for the terms and conditions (or terms of use) of the External Website. Further, you acknowledge and agree that you assume all risks resulting from entering and/or using the External Website and/or any linked websites.

BY ENTERING THE EXTERNAL WEBSITE, YOU ALSO ACKNOWLEDGE AND AGREE THAT YOU COMPLETELY AND IRREVOCABLY WAIVE ANY AND ALL RIGHTS AND CLAIMS AGAINST ATKINSRÉALIS, AND RELEASE, DISCHARGE, INDEMNIFY AND HOLD HARMLESS ATKINSRÉALIS, ITS OFFICERS, EMPLOYEES, DIRECTORS AND AGENTS FROM ANY AND ALL LIABILITY INCLUDING BUT NOT LIMITED TO LIABILITY FOR LOSS, DAMAGES, EXPENSES AND COSTS ARISING OUT OF OR IN CONNECTION WITH ENTERING AND/OR USING THE EXTERNAL WEBSITE AND/OR ANY LINKED WEBSITES AND ANY DATA AND/OR CONTENT CONTAINED THEREIN.

Such waiver and release specifically includes, without limitation, any and all rights and claims pertaining to reliance on the data or content of the External Website, or claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute. You also recognize by clicking “Accept” that the terms of this disclaimer are reasonable.

The information provided by Virtua Research cited herein is provided “as is” and “as available” without warranty of any kind. Use of any Virtua Research data is at a user’s own risk and Virtua Research disclaims any liability for use of the Virtua Research data. Although the information is obtained or compiled from reliable sources Virtua Research neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein. In no event shall Virtua Research be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Virtua Research further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

The consensus estimate provided by Virtua Research is based on estimates, forecasts and predictions made by third party financial analysts, as described above. It is not prepared based on information provided by AtkinsRéalis and can only be seen as a consensus view on AtkinsRéalis' possible future results from an outside perspective. AtkinsRéalis has not provided input on these forecasts, except by referring to past publicly disclosed information. AtkinsRéalis does not accept any responsibility for the quality or accuracy of any individual or average of forecasts or estimates. This web page contains forward-looking statements based on current assumptions and forecasts made by third parties. Various known and unknown risks, uncertainties and other factors could lead to material differences between AtkinsRéalis' actual future results, financial situation, development or performance, and the estimates given here.



Downloads

Trade releases